Bluejay Diagnostics Files 8-K for Bylaws and Exhibits
Ticker: BJDX · Form: 8-K · Filed: 2024-10-16T00:00:00.000Z
Sentiment: neutral
Topics: corporate-action, filing, financials
TL;DR
Bluejay Diagnostics filed an 8-K for corporate updates and financials.
AI Summary
On October 16, 2024, Bluejay Diagnostics, Inc. filed an 8-K report. The filing primarily concerns amendments to its articles of incorporation or bylaws and the submission of financial statements and exhibits. No specific financial figures or significant operational changes were detailed in the provided excerpt.
Why It Matters
This filing indicates routine corporate actions and the submission of required financial documents, suggesting ongoing compliance and operational processes for Bluejay Diagnostics.
Risk Assessment
Risk Level: low — The filing appears to be routine corporate housekeeping and submission of exhibits, with no immediate negative or positive financial or operational news.
Key Players & Entities
- Bluejay Diagnostics, Inc. (company) — Registrant
- October 16, 2024 (date) — Date of Report
- 360 Massachusetts Avenue, Suite 203 (address) — Principal executive offices
- Acton, MA 01720 (address) — City, State, Zip Code
FAQ
What specific amendments were made to Bluejay Diagnostics' articles of incorporation or bylaws?
The provided excerpt of the 8-K filing does not detail the specific amendments made to the articles of incorporation or bylaws; it only indicates that such amendments are part of the filing's subject matter.
What financial statements and exhibits are included in this 8-K filing?
The excerpt states that financial statements and exhibits are filed, but it does not list the specific documents included.
What is the primary purpose of this 8-K filing for Bluejay Diagnostics?
The primary purpose of this 8-K filing is to report amendments to the company's articles of incorporation or bylaws and to submit financial statements and exhibits.
When was this 8-K filing submitted to the SEC?
This 8-K filing was submitted to the SEC on October 16, 2024.
What is Bluejay Diagnostics' principal executive office address?
Bluejay Diagnostics, Inc.'s principal executive offices are located at 360 Massachusetts Avenue, Suite 203, Acton, MA 01720.
Filing Stats: 488 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2024-10-16 16:55:30
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share BJDX The Nasdaq Capital M
Filing Documents
- ea0217797-8k_bluejay.htm (8-K) — 26KB
- ea021779701ex3-1_bluejay.htm (EX-3.1) — 7KB
- 0001213900-24-088196.txt ( ) — 207KB
- bjdx-20241016.xsd (EX-101.SCH) — 3KB
- bjdx-20241016_lab.xml (EX-101.LAB) — 33KB
- bjdx-20241016_pre.xml (EX-101.PRE) — 22KB
- ea0217797-8k_bluejay_htm.xml (XML) — 4KB
03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On October 16, 2024, the Board of Directors (the "Board") of Bluejay Diagnostics, Inc. (the "Company") approved Amendment No. 1 to the Amended and Restated Bylaws of the Company for the purpose of reducing the threshold required to establish a quorum for its meetings of stockholders from a majority of shares entitled to vote at such meetings to one-third of the shares entitled to vote at such meetings. The amendment became effective upon adoption by the Board.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Number Description 3.1 Amendment No. 1 to Amended and Restated Bylaws of Bluejay Diagnostics, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURE Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Bluejay Diagnostics Inc. By: /s/ Neil Dey Name: Neil Dey Title: President and Chief Executive Officer Dated: October 16, 2024 2